$TNXP $NUVB $KALV $INSM
Brother… the SEC is too slow. I invest long for a reason. Maybe i will start “playing” the stocks… i have a few I REALLY want to short 🤫
H.C. Wainwright reiterated $PHVS Buy; $60 and said: European Academy of Allergy and Clinical Immunology (EAACI) 2026 reinforced deucrictibant's dual-use hereditary angioedema (HAE) profile across treatment settings.
$KALV IONS TAK $BCRX
Here's what H.C. Wainwright went on to say: https://x.com/Quantumup1/status/2066872400218575096?s=20
$FBIO starting to realize we could have made more on the prediction markets by getting Zycubo’s approvsl right and also the sale of the priority review voucher 🤷♂️ FBIOP is a drain on Fortress but c’est la vie
Lesson learned for $TNXP and others as well if I launch the educational platform on healthcare/ biopharma investing. 🤔
Like $NUVB and $KALV … I called all four approvals over the past 12 months (and avoided other duds). 4️⃣
Lesson learned! Back to work 💪
$KALV KalVista Pharmaceuticals (NASDAQ: KALV) became a special-case biotech after Chiesi’s $1.9 billion acquisition agreement. This rare disease stock now offers a lesson in how Big Pharma hunts for valuable biotech assets. https://biotechhealthx.com/biotech-news/is-kalvista-pharmaceuticals-kalv-one-of-the-most-overlooked-rare-disease-stocks-right-now/
$EWTX $IOVA $NRIX $KALV $REPL Small-cap biotech stocks are heating up as investors hunt for FDA catalysts, rare disease breakthroughs, cancer treatments, and Big Pharma buyout potential. These 10 biotech names could be among the most interesting stocks to watch now. https://biotechhealthx.com/biotech-news/top-10-small-cap-biotech-stocks-that-could-surge-100/
CLASSIC EXAMPLE TO SUPPORT PERFORMANCE OF SPM TAGS
$KALV $27.00 / BOOK SELL IN BALNCE OF LONG POSITION AT $27.00
DAC (dollar average cost includes partial SELLS at profit to reduce net cost to $0.89.
https://stocktwits.com/search/u/G101SPM?symbol=KALV
UPDATE:
KalVista Pharmaceuticals: Chiesi Group completes acquisition of KalVista Pharmaceuticals (27.00)
As a result of the merger, KalVista became a wholly owned subsidiary of Chiesi and KalVista's common stock ceased trading on the Nasdaq Global Market. Additional details regarding the tender can be found in a form 8-K filed by KalVista today with the Securities and Exchange Commission.
$KALV Chiesi Group Completes Acquisition of KalVista Pharmaceuticals
https://www.businesswire.com/news/home/20260610759093/en/Chiesi-Group-Completes-Acquisition-of-KalVista-Pharmaceuticals
On June 11, 2026, Chiesi successfully completed its tender offer for all outstanding shares of KalVista common stock for $27.00 per share in cash and accepted for payment all shares validly tendered and not validly withdrawn as of the expiration time of the tender offer, which shares represented approximately 77.8% of KalVista’s outstanding shares. Following completion of the offer, Chiesi completed its acquisition of KalVista through a merger of a wholly owned subsidiary of Chiesi with and into KalVista, in connection with which the outstanding shares of KalVista common stock were cancelled and converted into the right to receive the same $27.00 per share in cash.
$KALV Equity Corporate Actions Alert #2026 - 390
Information Regarding the Merger of KalVista Pharmaceuticals, Inc. (KALV)
https://www.nasdaqtrader.com/TraderNews.aspx?id=ECA2026-390
The tender offer by Skyline Merger Sub, Inc. a wholly owned subsidiary of Chiesi Farmaceutici S.p.A. to acquire all of the outstanding common stock of KalVista Pharmaceuticals, Inc. (KALV) is scheduled to expire one minute after 11:59 p.m. ET, on June 10, 2026, unless extended or terminated. The subsequent merger is tentatively scheduled to close prior to the market open on June 11, 2026. In anticipation of the closing, the stock will be halted immediately following the after-hours session at or around 7:50 p.m. on June 10, 2026. If the merger closes as planned, the stock will remain halted on the day of closing (June 11th) and will be suspended effective June 12, 2026.
$KALV filed their 14D9 with the SEC last Wednesday. The filing includes, among other things, the financial projection provided Chiesi that of course included an Eckterly revenue forecast.
The attachment compares the revenue forecast prepared by KALV mgmt/BOD to analyst consensus revenue estimates per Seeking Alpha. KALV's mgmt/BOD prepared 5 & 10-year revenue forecast was roughly 10% lower than analysts. We recall $SLNO mgmt/BOD prepared revenue forecast was lower but it's our experience the variance is usually the other way around.
This also means the revenue multiples paid were higher. The SLNO 5-year multiple was 0.70 where KALV's was 1.02X.
KALV projected a gross margin of 87.4% over the first 10 years of Eckterly's launch.
As always, this is not investment advice. We're merely sharing analysis.
$XBI $IBB
$KALV Tender offer has officially commenced
https://www.sec.gov/Archives/edgar/data/1348911/000114036126020935/ny20071872x1_sctot.htm
• Expires 1 minute after 11:59pm ET on June 10, unless extended.
• At least 50% of outstanding shares must be tendered for deal to close.
• Tender offer is $27.00 per share
Full tender offer: https://www.sec.gov/Archives/edgar/data/1348911/000114036126020935/ny20071872x1_exa1a.htm
